AbbVie Inc (ABBV)vsCorMedix Inc (CRMD)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
CRMD
CorMedix Inc
$7.48
-1.19%
HEALTHCARE · Cap: $586.55M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 19521% more annual revenue ($61.16B vs $311.71M). CRMD leads profitability with a 52.3% profit margin vs 6.9%. CRMD trades at a lower P/E of 3.6x. CRMD earns a higher WallStSmart Score of 70/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
CRMD
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for CRMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 67 in profit
Keeps 52 of every $100 in revenue as profit
Strong operational efficiency at 53.9%
Revenue surging 312.1% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
Earnings declined 28.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 52.3% and operating margin at 53.9%. Revenue growth of 312.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : CRMD
The primary concerns for CRMD are Market Cap, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while CRMD is a growth play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.41 — expect wider price swings.
CRMD is growing revenue faster at 312.1% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (70/100 vs 63/100), backed by strong 52.3% margins and 312.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?